Palatin Pharmaceuticals reported revenue growth in Q2 FY2026, driven by collaborations, while significantly enhancing its balance sheet through a successful public offering. Net losses increased as the company invested heavily in advancing its obesity-focused drug pipeline.

• Completed an upsized public offering raising $18.2 million, restoring compliance with NYSE listing standards.
• Revenue for the quarter was $116,000, marking a significant increase from zero in the prior year, due primarily to collaborations.
• Operating expenses rose to $7.4 million, attributed to increased investments in obesity programs and higher compensation costs.
• Net loss widened to $7.3 million, reflecting the absence of prior year's sale gains and ongoing R&D expenditures.
• Cash position improved to $14.5 million, providing sufficient runway into FY2027 to advance ongoing clinical programs.